Sanofi and Regeneron expand global alliance with multiple next-generation, long-acting immunology antibodies
The alliance expansion likely increases development and future availability of immunology antibody therapies.
Source →The trace
How it reaches your house.
Starting from Sanofi, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Sanofi →Stands to benefitRegeneron Pharmaceuticals, Inc.REGN
Sanofi's expanded alliance directly benefits Regeneron via a $1 billion upfront payment, potential milestone payments, and equal sharing of development/commercialization costs and future profits for the added long-acting immunology antibodies.
97% confidenceHop 2
Regeneron Pharmaceuticals, Inc. →Stands to benefitSanofiSNY
The alliance expansion directly involves Sanofi, and Regeneron already states it supplies commercial bulk product to Sanofi under their collaboration, so Sanofi should benefit from greater development output and future product availability.
92% confidenceHop 3